# Phage Therapeutics Sector

Canonical URL: https://biopharmsignal.com/sector/phage-therapeutics

Phage Therapeutics includes companies using bacteriophages to target bacterial infections. These programs are often positioned as alternatives or complements to traditional antibiotics, especially in resistant or difficult-to-treat infections.

Companies currently grouped under Phage Therapeutics: 4

## Recent Sector News

- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9) — Source: Enlivex Therapeutics
- 2026-06-02 08:00 EST — ENLV — [ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026](https://biopharmsignal.com/news/ENLV/enlivex-to-present-quality-longevity-model-powered-by-prediction-markets-treasury-at-proof-of-talk-2026) — Source: Enlivex Therapeutics
- 2026-06-01 08:00 EST — ENLV — [Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026](https://biopharmsignal.com/news/ENLV/allocetra-shows-durable-6-month-efficacy-in-knee-osteoarthritis-phase-iia-trial-oral-presentation-at-eular-2026) — Source: Enlivex Therapeutics
- 2026-05-28 08:00 EST — ENLV — [Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-rain-holdings-valued-at-approximately-1-16-billion-rain-foundation-appoints-industry-leaders-to-advisory-board) — Source: Enlivex Therapeutics
- 2026-05-27 08:00 EST — ENLV — [Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-rain-protocol-jumps-into-top-three-global-prediction-markets-in-league-table-following-100m-in-additional-liquidity) — Source: Enlivex Therapeutics
- 2026-05-18 08:00 EST — ENLV — [Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis](https://biopharmsignal.com/news/ENLV/enlivex-announces-dosing-of-first-patient-in-the-united-states-as-part-of-its-phase-2b-trial-of-allocetra-in-age-related-primary-moderate-to-severe-knee-osteoarthritis) — Source: Enlivex Therapeutics
- 2026-05-15 16:10 EST — ENLV — [Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification](https://biopharmsignal.com/news/ENLV/enlivex-announces-receipt-of-nasdaq-minimum-bid-price-notification) — Source: Enlivex Therapeutics
- 2026-05-14 12:00 EST — LUCD — [Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-provides-business-update-and-reports-first-quarter-2026-financial-results) — Source: Lucid Diagnostics
- 2026-04-30 12:31 EST — LUCD — [Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-to-hold-first-quarter-2026-business-update-conference-call-and-ef5e4a87) — Source: Lucid Diagnostics
- 2026-04-30 08:30 EST — ENLV — [Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-listing-of-the-rain-token-on-htx-a-leading-cryptocurrency-exchange) — Source: Enlivex Therapeutics
- 2026-04-28 08:30 EST — ENLV — [Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million](https://biopharmsignal.com/news/ENLV/enlivex-treasury-update-total-rain-holdings-rise-to-78-819-756-062-tokens-as-of-april-27-2026-representing-an-aggregated-value-of-567-million) — Source: Enlivex Therapeutics
- 2026-04-24 14:23 EST — LUCD — [Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-announces-closing-of-18-million-underwritten-offering-of-common-stock) — Source: Lucid Diagnostics
- 2026-04-23 12:30 EST — LUCD — [Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-announces-18-million-underwritten-offering-of-common-stock) — Source: Lucid Diagnostics
- 2026-04-23 08:30 EST — ENLV — [Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress](https://biopharmsignal.com/news/ENLV/enlivex-to-present-phase-iia-3-month-and-6-month-data-of-allocetra-at-oarsi-2026-world-congress) — Source: Enlivex Therapeutics
- 2026-04-21 08:30 EST — ENLV — [Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis](https://biopharmsignal.com/news/ENLV/enlivex-announces-second-regulatory-approval-for-phase-2b-trial-of-allocetra-in-age-related-primary-moderate-to-severe-knee-osteoarthritis) — Source: Enlivex Therapeutics
- 2026-04-09 12:01 EST — LUCD — [Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-to-participate-in-fireside-chat-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: Lucid Diagnostics
- 2026-04-08 08:30 EST — ENLV — [Ondo Global Markets Tokenizes Enlivex's Ordinary Shares](https://biopharmsignal.com/news/ENLV/ondo-global-markets-tokenizes-enlivex-s-ordinary-shares) — Source: Enlivex Therapeutics
- 2026-03-26 12:00 EST — LUCD — [Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results) — Source: Lucid Diagnostics
- 2026-03-26 08:30 EST — ENLV — [Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt](https://biopharmsignal.com/news/ENLV/enlivex-rain-update-rain-launches-an-openclaw-and-ai-agent-interface-allowing-anyone-to-create-a-prediction-market-via-a-single-prompt) — Source: Enlivex Therapeutics
- 2026-03-25 08:30 EST — ENLV — [Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48](https://biopharmsignal.com/news/ENLV/enlivex-reports-full-year-2025-results-profit-net-income-of-1-23-billion-and-diluted-earnings-per-share-eps-of-25-48) — Source: Enlivex Therapeutics

## Companies

- [ARMP](https://biopharmsignal.com/company/ARMP) — Armata Pharmaceuticals
- [CARM](https://biopharmsignal.com/company/CARM) — Carisma Therapeutics, Inc.
- [ENLV](https://biopharmsignal.com/company/ENLV) — Enlivex Therapeutics
- [LUCD](https://biopharmsignal.com/company/LUCD) — Lucid Diagnostics